Targeting Mitochondrial Dysfunction
Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.
View Candidate
Innovative Pipeline of First-In-Class Products
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View Pipeline
Backed by Strong Leadership
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
Latest News
Poxel Announces Completion of Patient Enrollment for TIMES 2 Trial in Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan
Phase 3 TIMES 1, TIMES 2 and TIMES 3 trials for Imeglimin are now fully enrolled with over 1,100 patients Phase 3 TIMES data results are on track for 2019 …
Read this Press Release: Poxel Announces Completion of Patient Enrollment for TIMES 2 Trial in Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in JapanPoxel Presents Complete PXL770 Phase 1 Results, Cardiac Safety Profile and Preclinical Efficacy Data in NASH at AMPK - From Mechanisms to New Therapies Scientific Congress
Phase 1 clinical program for PXL770 was observed to have a favorable pharmacokinetic, tolerability and safety profile PXL770 was observed to have a favorable cardiac safety…
Read this Press Release: Poxel Presents Complete PXL770 Phase 1 Results, Cardiac Safety Profile and Preclinical Efficacy Data in NASH at AMPK - From Mechanisms to New Therapies Scientific CongressPoxel Reports Financial Results for the First Half 2018 and Provides Corporate Update
Executed strategic agreement for Imeglimin with Roivant Sciences, which included USD 35 million upfront payment, and potential for up to USD 600 million in regulatory and development milestone payments and…
Read this Press Release: Poxel Reports Financial Results for the First Half 2018 and Provides Corporate Update
